We provide you with 20 years of free, institutional-grade data for ANEB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANEB. Explore the full financial landscape of ANEB stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-05-15 | 1815974 | ANEB | 10-Q | Url |
| 2024-02-13 | 1815974 | ANEB | 10-Q | Url |
| 2023-11-14 | 1815974 | ANEB | 10-Q | Url |
| 2023-09-22 | 1815974 | ANEB | 10-K | Url |
| 2023-05-11 | 1815974 | ANEB | 10-Q | Url |
| 2023-02-10 | 1815974 | ANEB | 10-Q | Url |
| 2022-11-10 | 1815974 | ANEB | 10-Q | Url |
| 2022-11-02 | 1815974 | ANEB | S-1 | Url |
| 2022-09-09 | 1815974 | ANEB | 10-K | Url |
| 2022-05-11 | 1815974 | ANEB | 10-Q | Url |
| 2022-02-11 | 1815974 | ANEB | 10-Q | Url |
Anebulo Pharmaceuticals Inc(NASDAQ:ANEB) 
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
Website: https://www.anebulo.com/
Founded: 2020
Founder: Joseph F. Lawler
CEO: Daniel Schneeberger
Sector:
Industry:
Share this website to your friends
The information provided in this report about ANEB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.